Introduction

Something significant is happening in UK aesthetic medicine, and every clinic owner reading this will already have felt it. The way patients think about aesthetic treatment has shifted. The requests coming through your booking system in 2026 are different to the ones you were fielding in 2023.

This is not a fad, and it is not opinion. It is backed by hard market data. According to Grand View Research, the UK skin booster market generated USD 61.2 million (approximately £48 million) in revenue in 2025 and is projected to reach USD 175.2 million (approximately £137 million) by 2033, growing at a compound annual growth rate of 14 per cent. Within that market, mesotherapy is the largest and fastest growing sub segment, and the UK is the fastest growing regional market in Europe.

The commercial question for UK clinics is not whether to offer skin boosters. It is how to deliver them at a clinical standard and at a volume that turns a rising treatment category into a genuinely scalable revenue stream.

In a recent Instalive with Novus Medical, Kate Monteith Ross, one of the UK's most respected aesthetic nurse practitioners, shared how she has approached this exact question at her clinic. Her answer was direct. The Dermashine Pro has become the delivery method that allows her to serve rising booster demand at a standard she is happy to put her name to.

About Kate Monteith-Ross

Kate Monteith-Ross is an experienced Nurse Practitioner, Independent Prescriber, and wound care specialist, with qualifications including a Bachelor's degree, Master's degree, PGCE, and Independent and Supplementary Prescribing certification. She is currently undertaking a Doctorate in Education, focusing on leadership within aesthetic medicine.

Kate is the owner of an award-winning, CQC-registered clinic in the South of England, delivering advanced aesthetic, medical, regenerative, and biohacking treatments.

An internationally recognised Key Opinion Leader for Dermalux, Neogen and Jalupro, Kate has delivered educational presentations in 27 countries and was the first UK nurse to present at both AMWC China and the NSS in Sydney.

Passionate about education and innovation, Kate regularly publishes internationally on emerging topics shaping the aesthetic industry. She is Director of The Clinic, Urban Training Academy, and The Patient Recovery Network, and Co-founder and Director of The Nurses Network and The Aesthetic Pages.

Kate has been featured in national media for her pioneering work in managing complications following overseas cosmetic surgery and has appeared in Vogue, Top Santé and Platinum magazine.

The market shift, backed by data

Filler is not disappearing, but the way patients think about it, and the way they book aesthetic treatments overall, is changing meaningfully.

The most striking indicator sits in UK Google search data. According to a five year analysis by SEO analyst Jane Nriapia published in March 2026, UK searches for polynucleotides overtook searches for dermal fillers for the first time in early 2024. In a category where dermal filler has been the dominant injectable for over two decades, that is a genuine inflection point. It tells you what patients are researching before they book, and by extension, what they are asking for at consultation.

The UK aesthetic register Save Face identified the shift from HA filler for volume to regenerative medicine as the single biggest trend of 2026, framing it as patients wanting "treatments that make their skin work harder, rather than just filling a gap." Marie Claire UK reported that 47 per cent of people who have had dermal filler have subsequently had it dissolved, with the rate significantly higher among 18 to 34 year olds. Patients have been through the fill everything phase, and many of them do not want to go back.

The commercial consequence is a rapid reallocation of aesthetic spend. Patients who spent the last decade on filler are increasingly booking polynucleotides, Profhilo, Sunekos, Jalupro and mesotherapy cocktails. The market research firm Grand View forecasts that UK skin booster revenue will grow at 14 per cent CAGR to 2033, roughly tripling over the eight year window. Within that category, mesotherapy is the fastest growing segment, and the UK is the fastest growing regional market in Europe.

On the Instalive, Kate offered a sharper front line view. Her professional observation, based on what she is seeing in her own booking system and the conversations she is having with practitioners across her training network, is that skin booster demand is growing rapidly and that the current pace on the ground feels faster than an averaged market forecast can capture. Both the market research and the clinical front line point in the same direction. The clinical front line just sees it happening faster.

For clinic owners, the implication is clear. Either build a skin booster offering that can scale with that demand, or watch patients walk to a competitor clinic that has.

The delivery bottleneck

The problem, as any clinic already offering boosters manually will know, is that delivering boosters at volume is hard.

The current standard manual technique across UK clinics is intradermal injection with visible papules, typically at around 1cm spacing across the treatment area. Skilled practitioners can perform this well. But manually, at true full face coverage, it takes 30 to 45 minutes of active injection time per patient. Most clinics cannot justify that appointment length at the price patients are willing to pay, so they compromise on site count. A full face booster treatment at one clinic might be 200 sites. At another it might be 50. Both are marketed to patients as full face.

The clinical consequence is inconsistent results. The commercial consequence is that clinics cannot scale booster volume without either sacrificing coverage, extending appointment times, or adding practitioner hours. All three options hurt margin.

Kate's clinic hit that bottleneck. Her clinical standards did not allow her to cut corners on site count, and her commercial reality did not allow her to extend appointments beyond what patients would pay for. She needed a way to deliver a proper clinical booster treatment at a speed and consistency that made it scalable.

What Kate said about the Dermashine Pro

Kate described the difference in plain terms on the Instalive.

With the Dermashine Pro, she is now able to deliver 1,250 individual injection sites in five minutes of active injection time, at exactly the same depth and the same flow rate for every single shot.

That is the number she has been quoting to her patients and to the practitioners she trains. Not because it is a marketing line, but because it is what the device actually does.

The clinical consequences she highlighted:

Every patient gets full coverage. Not 50 sites. Not 200. Twelve hundred and fifty. Every time.

Every practitioner in her clinic delivers the same treatment. The clinical outcome is defined by the device protocol, not by which nurse happens to be in the treatment room that day.

Product distribution is even across the dermis. The product does what the manufacturer designed it to do, because it is placed where the manufacturer designed it to go.

Treatment time drops significantly. The five minutes of active injection means the total appointment can be structured around consultation, cleansing, treatment and patient education, not around 45 minutes of manual injection work.

Kate's summary, in her own words on the Instalive, was that the Dermashine Pro has given her a scalable way to deliver premium skin boosters at the clinical standard she wants, without the trade off she used to have to make between coverage and appointment length.

Why this matters for the next eight years

Pull the market data and the clinical reality together and the picture is straightforward.

The market is growing meaningfully. UK skin booster revenue is forecast to grow from £48 million in 2025 to £137 million by 2033. Roughly tripling. Mesotherapy is the fastest growing sub segment within that. The UK is the fastest growing regional market in Europe. This is not a category to sit out of.

Manual delivery does not scale. The bottleneck is real, it is physical, and no amount of clinical skill will remove it. There is only so fast a human hand can inject, and only so many hours a nurse can spend with a needle in her hand across a working day. Clinics attempting to capture their share of a rapidly growing market with manual delivery only will hit a hard ceiling.

Automated delivery is the path to scale. The Dermashine Pro takes what would take 45 minutes manually and delivers it in five minutes of active injection, at higher site count, with better consistency, and with reduced product wastage per patient.

Front line signals are hotter than the average. Grand View forecasts 14 per cent CAGR averaged over an eight year window. Practitioners like Kate report seeing rapid growth on the ground right now. The early part of a growth curve is always steeper than the average, and clinics that build capacity for the current pace of growth will capture disproportionate market share while competitors are still deciding whether the shift is real.

For a clinic serious about skin boosters as a growth category over the next five to eight years, the maths is straightforward. Scalable delivery is not a nice to have. It is the constraint that will decide which clinics grow and which clinics get overtaken.

What this looks like commercially

The Dermashine Pro is £12,000 ex VAT. Leasing options are available, including a 0% finance lease, subject to terms and conditions. Clinical training and ongoing UK based support are included.

For a clinic already offering skin boosters manually, adding the device typically pays for itself within the first year through a combination of increased treatment volume, reduced appointment time per patient, and improved product efficiency per vial.

For a clinic launching a booster offering from scratch, the device allows you to launch at a clinical standard that supports premium pricing from day one, which matters when you are competing for early customers in a rising treatment category.

Next steps

The best way to understand what the Dermashine Pro can do for your clinic is to see it in action. We offer live demonstrations at your clinic or online, including full face booster protocol walkthroughs.

If you would prefer to speak directly with a practitioner using the device day to day, Kate Monteith Ross and the wider Novus Medical ambassador network are available to answer clinical questions from prospective clinic owners.

Book a live demonstration or get in touch to discuss whether the Dermashine Pro is the right fit for your booster offering.